Co-Founder & Managing Partner, Lux Capital

Josh co-founded Lux Capital in NYC and Menlo Park to support scientists andentrepreneurs who pursue counter-conventional solutions to the most vexing puzzles of our time. Josh is a Director at Shapeways (3D printing), Strateos (robotic and digital pathology), Kymeta (making cutting-edge technology for high-speed satellite and space communications), Varda Space Industries (manufacturing in low and zero gravity space), and Variant (developing therapies that will improve global health by studying the genes of people with exceptional health-related traits). Josh helped lead many of the firm’s investments across cutting-edge technologies including Anduril (defense), Hadrian (aerospace manufacturing), Resilience (biopharma manufacturing) Kurion (high-tech nuclear waste remediation, acquired by Veolia), Kallyope (gut-brain axis), and CTRL-Labs (brain- machine interface acquired by Facebook).

Josh is a published scientist and Westinghouse semi-finalist. Before founding Lux, Josh worked in investment banking at Salomon Smith Barney, in capital markets at Merrill Lynch, and published AIDS-immunopathology research in Cell Vision & The Journal of Leukocyte Biology. Josh has been a columnist and editor with Forbes. He has been invited to The White House and Capitol Hill to advise on emerging technologies, and a lecturer at MIT, Harvard, Yale, Cornell, Columbia, and NYU. He is a Trustee of the Santa Fe Institute, has been a term member at The Council on Foreign Relations, and Chairman of Coney Island Prep charter school, where he grew up in Brooklyn. He graduated from Cornell University with a B.S. in Economics and Finance.